Taiwan · Delayed Price · Currency is TWD RBC Bioscience Statistics
Total Valuation
RBC Bioscience has a market cap or net worth of TWD 276.91 million. The enterprise value is 631.64 million.
| Market Cap | 276.91M |
| Enterprise Value | 631.64M |
Important Dates
The last earnings date was Tuesday, August 18, 2026.
| Earnings Date | Aug 18, 2026 |
| Ex-Dividend Date | Sep 2, 2026 |
Share Statistics
RBC Bioscience has 14.27 million shares outstanding. The number of shares has decreased by -0.05% in one year.
| Current Share Class | 14.27M |
| Shares Outstanding | 14.27M |
| Shares Change (YoY) | -0.05% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 29.02% |
| Owned by Institutions (%) | n/a |
| Float | 8.08M |
Valuation Ratios
The trailing PE ratio is 13.18.
| PE Ratio | 13.18 |
| Forward PE | n/a |
| PS Ratio | 1.26 |
| PB Ratio | 1.06 |
| P/TBV Ratio | 1.13 |
| P/FCF Ratio | 6.60 |
| P/OCF Ratio | 6.69 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.82, with an EV/FCF ratio of 15.06.
| EV / Earnings | 30.00 |
| EV / Sales | 2.86 |
| EV / EBITDA | 14.82 |
| EV / EBIT | 23.60 |
| EV / FCF | 15.06 |
Financial Position
The company has a current ratio of 1.08, with a Debt / Equity ratio of 1.37.
| Current Ratio | 1.08 |
| Quick Ratio | 0.61 |
| Debt / Equity | 1.37 |
| Debt / EBITDA | 8.34 |
| Debt / FCF | 8.47 |
| Interest Coverage | 2.92 |
Financial Efficiency
Return on equity (ROE) is 8.09% and return on invested capital (ROIC) is 3.72%.
| Return on Equity (ROE) | 8.09% |
| Return on Assets (ROA) | 2.26% |
| Return on Invested Capital (ROIC) | 3.72% |
| Return on Capital Employed (ROCE) | 4.44% |
| Weighted Average Cost of Capital (WACC) | 4.01% |
| Revenue Per Employee | 4.41M |
| Profits Per Employee | 421,160 |
| Employee Count | 50 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 2.41 |
Taxes
In the past 12 months, RBC Bioscience has paid 5.40 million in taxes.
| Income Tax | 5.40M |
| Effective Tax Rate | 20.39% |
Stock Price Statistics
The stock price has increased by +25.99% in the last 52 weeks. The beta is 0.41, so RBC Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | +25.99% |
| 50-Day Moving Average | 20.38 |
| 200-Day Moving Average | 18.11 |
| Relative Strength Index (RSI) | 63.75 |
| Average Volume (20 Days) | 42,734 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RBC Bioscience had revenue of TWD 220.60 million and earned 21.06 million in profits. Earnings per share was 1.47.
| Revenue | 220.60M |
| Gross Profit | 101.60M |
| Operating Income | 26.77M |
| Pretax Income | 26.45M |
| Net Income | 21.06M |
| EBITDA | 41.40M |
| EBIT | 26.77M |
| Earnings Per Share (EPS) | 1.47 |
Balance Sheet
The company has 43.18 million in cash and 355.37 million in debt, with a net cash position of -312.19 million or -21.87 per share.
| Cash & Cash Equivalents | 43.18M |
| Total Debt | 355.37M |
| Net Cash | -312.19M |
| Net Cash Per Share | -21.87 |
| Equity (Book Value) | 260.09M |
| Book Value Per Share | 18.27 |
| Working Capital | 10.34M |
Cash Flow
In the last 12 months, operating cash flow was 41.40 million and capital expenditures 543,000, giving a free cash flow of 41.95 million.
| Operating Cash Flow | 41.40M |
| Capital Expenditures | 543,000 |
| Depreciation & Amortization | 14.63M |
| Net Borrowing | -48.44M |
| Free Cash Flow | 41.95M |
| FCF Per Share | 2.94 |
Margins
Gross margin is 46.05%, with operating and profit margins of 12.13% and 9.55%.
| Gross Margin | 46.05% |
| Operating Margin | 12.13% |
| Pretax Margin | 11.99% |
| Profit Margin | 9.55% |
| EBITDA Margin | 18.77% |
| EBIT Margin | 12.13% |
| FCF Margin | 19.01% |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 6.82%.
| Dividend Per Share | 1.50 |
| Dividend Yield | 6.82% |
| Dividend Growth (YoY) | 300.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 20.33% |
| Buyback Yield | 0.05% |
| Shareholder Yield | 6.80% |
| Earnings Yield | 7.60% |
| FCF Yield | 15.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 11, 2025. It was a forward split with a ratio of 1.1.
| Last Split Date | Aug 11, 2025 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |